The UK quality treatment biotech Freeline Therapeutics is to get speculation worth €72M (£61.1M) from the UK VC firm Syncona in a Series C round to finance the clinical improvement of quality treatments for the blood issue hemophilia B, Fabry illness, and other uncommon conditions. Of the €72M duty, Syncona has just wired €36M to Freeline. Freeline will get the remainder of the cash at an undisclosed later date. The ....
Tags : freeline, united kingdom, quality, treatment, encoding,
comments (0)